Aquestive Therapeutics Inc Announces Positive EPIPHAST II Trial Data for AQST-109 When Compared to EpiPen Call Transcript
Good day, and welcome to the EPIPHAST II update call. (Operator Instructions). As a reminder, this call may be recorded.
I would now like to turn the call over to Dan Barber, CEO of Aquestive Therapeutics. You may begin.
Thank you, operator, and good morning, everyone. Thank you for joining the call today. We appreciate your time and continued engagement.
Before I begin, you will see that we have included our company cautionary forward-looking statements made under the Safe Harbor provisions of securities laws on Slide 2 of our presentation. As a reminder, information included in this presentation is based on the company's review and evaluation of the clinical data regarding AQST-109. All conclusions and determinations contained in this presentation are subject to the company's further analysis of the clinical data. The ultimate determination of the safety and efficacy of AQST-109 will be made by the FDA. We ask that you keep these cautionary statements in mind when
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |